Ranbaxy Officially Becomes A Daiichi Subsidiary As Management Turns To Business Synergies

MUMBAI - Daiichi Sankyo has acquired 52.5 percent of Ranbaxy's equity share capital for $736 million. Ranbaxy announced that the committee of the board of directors of Ranbaxy approved Oct. 20 the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo. With this Ranbaxy has officially become a subsidiary of Daiichi Sankyo